SeaCrest Wealth Management LLC boosted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,670 shares of the company’s stock after purchasing an additional 583 shares during the period. Johnson & Johnson comprises approximately 1.2% of SeaCrest Wealth Management LLC’s holdings, making the stock its 9th largest holding. SeaCrest Wealth Management LLC’s holdings in Johnson & Johnson were worth $7,693,000 at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the stock. Lathrop Investment Management Corp grew its stake in shares of Johnson & Johnson by 1.4% in the 2nd quarter. Lathrop Investment Management Corp now owns 4,901 shares of the company’s stock worth $689,000 after buying an additional 69 shares during the last quarter. Reik & CO. LLC grew its stake in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Reik & CO. LLC now owns 17,727 shares of the company’s stock worth $2,493,000 after buying an additional 70 shares during the last quarter. Wealth Architects LLC grew its stake in shares of Johnson & Johnson by 1.5% in the 3rd quarter. Wealth Architects LLC now owns 4,719 shares of the company’s stock worth $702,000 after buying an additional 70 shares during the last quarter. Westhampton Capital LLC grew its stake in shares of Johnson & Johnson by 0.5% in the 3rd quarter. Westhampton Capital LLC now owns 13,255 shares of the company’s stock worth $1,973,000 after buying an additional 70 shares during the last quarter. Finally, Delta Investment Management LLC grew its stake in shares of Johnson & Johnson by 1.0% in the 2nd quarter. Delta Investment Management LLC now owns 7,406 shares of the company’s stock worth $1,041,000 after buying an additional 71 shares during the last quarter. Institutional investors own 67.44% of the company’s stock.
In related news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares of the company’s stock, valued at approximately $10,233,336.16. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.27% of the stock is currently owned by company insiders.
Several analysts recently weighed in on the company. Credit Suisse Group upped their price target on Johnson & Johnson from $163.00 to $168.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 14th. Stifel Nicolaus cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Cantor Fitzgerald upped their price objective on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research report on Wednesday, October 14th. Raymond James reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Friday, November 20th. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Monday, August 3rd. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $164.93.
NYSE JNJ opened at $143.68 on Friday. The business’s fifty day moving average price is $145.31 and its 200-day moving average price is $146.47. The stock has a market capitalization of $378.24 billion, a price-to-earnings ratio of 22.59, a PEG ratio of 3.04 and a beta of 0.69. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. Johnson & Johnson has a 1-year low of $109.16 and a 1-year high of $157.00.
Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Sunday, October 18th. The company reported $2.20 EPS for the quarter, topping the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The company had revenue of $21.08 billion for the quarter, compared to analysts’ expectations of $20.15 billion. During the same period last year, the firm earned $2.12 EPS. Johnson & Johnson’s revenue for the quarter was up 1.7% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 7.99 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.01 dividend. The ex-dividend date is Monday, November 23rd. This represents a $4.04 dividend on an annualized basis and a yield of 2.81%. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
About Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.